ArticleZeitschrift fur Rheumatologie2021

Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in active rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs.

Y H Lee et al.PubMed ↗Publisher ↗

No numbers read from the abstract.